JAMA Network
About The Study: In this single-center cohort study, both bariatric surgery and semaglutide or tirzepatide treatment were associated with substantial fat mass loss, moderate fat-free mass (FFM) loss, and improved FFM to fat mass ratio. These findings provide evidence to guide interventions aimed at preserving FFM while promoting fat loss.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
